These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1247 related items for PubMed ID: 24885803

  • 1. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, Cappuzzo F, Melfi F, Lucchi M, Mussi A, Fontanini G.
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [Abstract] [Full Text] [Related]

  • 2. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ.
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [Abstract] [Full Text] [Related]

  • 3. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D, Wang Z, Yang L, Mu X, Wang Y, Zhao X, Li J, Lin D.
    Oncotarget; 2016 Sep 27; 7(39):64410-64420. PubMed ID: 27418132
    [Abstract] [Full Text] [Related]

  • 4. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
    Wu YC, Chang IC, Wang CL, Chen TD, Chen YT, Liu HP, Chu Y, Chiu YT, Wu TH, Chou LH, Chen YR, Huang SF.
    PLoS One; 2013 Sep 27; 8(8):e70839. PubMed ID: 23951022
    [Abstract] [Full Text] [Related]

  • 5. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
    Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT.
    Clin Cancer Res; 2013 Aug 01; 19(15):4273-81. PubMed ID: 23729361
    [Abstract] [Full Text] [Related]

  • 6. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC.
    J Thorac Oncol; 2012 Jan 01; 7(1):98-104. PubMed ID: 22124476
    [Abstract] [Full Text] [Related]

  • 7. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W, Zhang J, Guo L, Chuai S, Shan L, Ying J.
    J Thorac Oncol; 2017 Jan 01; 12(1):94-101. PubMed ID: 27614248
    [Abstract] [Full Text] [Related]

  • 8. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G, Seto T.
    Respir Investig; 2014 Nov 01; 52(6):330-8. PubMed ID: 25453376
    [Abstract] [Full Text] [Related]

  • 9. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.
    Tiseo M, Gelsomino F, Bartolotti M, Bordi P, Bersanelli M, Rossi G, Ardizzoni A.
    Expert Rev Anticancer Ther; 2011 Nov 01; 11(11):1677-87. PubMed ID: 22050016
    [Abstract] [Full Text] [Related]

  • 10. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.
    Oncologist; 2016 Jun 01; 21(6):762-70. PubMed ID: 27245569
    [Abstract] [Full Text] [Related]

  • 11. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
    V Laffert M, Warth A, Penzel R, Schirmacher P, Jonigk D, Kreipe H, Schildhaus HU, Merkelbach-Bruse S, Büttner R, Reu S, Kerler R, Jung A, Kirchner T, Wölfel C, Petersen I, Rodriguez R, Jochum W, Bartsch H, Fisseler-Eckhoff A, Berg E, Lenze D, Dietel M, Hummel M.
    Lung Cancer; 2013 Aug 01; 81(2):200-6. PubMed ID: 23669200
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Shen Q, Wang X, Yu B, Shi S, Liu B, Wang Y, Xia Q, Rao Q, Zhou X.
    Lung Cancer; 2015 Dec 01; 90(3):492-8. PubMed ID: 26477969
    [Abstract] [Full Text] [Related]

  • 15. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C, Li PM, Gainor JF, Stopyra GA, Friedman EL.
    J Thorac Oncol; 2015 Jul 01; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract] [Full Text] [Related]

  • 16. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.
    McLeer-Florin A, Moro-Sibilot D, Melis A, Salameire D, Lefebvre C, Ceccaldi F, de Fraipont F, Brambilla E, Lantuejoul S.
    J Thorac Oncol; 2012 Feb 01; 7(2):348-54. PubMed ID: 22071784
    [Abstract] [Full Text] [Related]

  • 17. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S, Villaruz LC, Abberbock S, Mahaffey A, Incharoen P, Nikiforova MN.
    Oncotarget; 2016 Dec 13; 7(50):82943-82952. PubMed ID: 27769042
    [Abstract] [Full Text] [Related]

  • 18. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH, Jeon YK, Chung DH, Heo DS.
    Lung Cancer; 2012 Aug 13; 77(2):288-92. PubMed ID: 22465695
    [Abstract] [Full Text] [Related]

  • 19. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A.
    Lung Cancer; 2014 Feb 13; 83(2):168-73. PubMed ID: 24380695
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.